Investor Presentaiton
Major R&D Pipeline: 5DXd-ADCS
As of Jul 2023
Daiichi-Sankyo
(US/EU/Asia) HER2+ BC 2L+/1L
DESTINY-Breast07
(US/EU/Asia) HER2 low BC
Chemo naïve/ post chemo
DESTINY-Breast08
(JP/US/EU/Asia) HER2+ GC combo, 2L+/1L
DESTINY-Gastric03
(durvalumab combo) 1L
(US/EU/Asia) HER2+ NSCLC
DESTINY-Lung03
(US/EU) BC, bladder
(nivolumab combo)
(US/EU) BC, NSCLC
(pembrolizumab combo)
(US/EU/Asia) solid tumors
(AZD5305 combo)
PETRA
DS-7300 (JP/US)
ESCC, CRPC, squamous NSCLC, SCLC, etc.
Phase 1
(JP/US) solid tumors
TROPION-PanTumor01
(CN) NSCLC, TNBC
TROPION-PanTumor02
(JP/US/EU/Asia) NSCLC (w/o AGA,
pembrolizumab combo)
TROPION-Lung02
(JP/US/EU) NSCLC (w/o AGA,
durvalumab, AZD2936 and MEDI5752
combo) TROPION-Lung04
(JP/US/EU/Asia) solid tumors
(AZD5305 combo)
PETRA
(JP/US/EU/Asia) NSCLC
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(CN) HER2+ GC 3L
DESTINY-Gastric06
(CN) HER2 mutant NSCLC 2L+
DESTINY-Lung05
(US/EU/Asia) NSCLC
(durvalumab combo) 2L+
HUDSON
(JP/US/EU) HER2+ CRC 3L
DESTINY-CRC01
(JP/US/EU/Asia) HER2+ CRC 3L
DESTINY-CRC02
(JP/US) EGFR mutated NSCLC
(osimertinib combo)
(JP/US) HER3+ BC
(JP/US/EU/Asia)
HER2 mutant tumor
DESTINY-PanTumor01
(US/EU/Asia)
HER2 expressing tumor
DESTINY-PanTumor02
Phase 2
(JP/US/EU/Asia) solid tumors
TROPION-PanTumor03
(JP/US/EU/Asia) NSCLC (w/ AGA)
TROPION-Lung05
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(JP/US/EU/Asia) EGFR mutated
NSCLC (osimertinib combo) 2L
ORCHARD
(US/EU/Asia) resectable early-stage
NSCLC (durvalumab combo) neoadjuvant
NeoCOAST-2
(JP/US/EU/Asia) EGFR mutated
NSCLC 3L
HERTHENA-Lung01
DS-7300 (JP/US/EU/Asia)
ES-SCLC
Phase 3
(JP/US/EU/Asia) HER2+ BC
adjuvant*1
DESTINY-Breast05
(UP/US/EU/Asia) HER2 low BC
chemo naïve
DESTINY-Breast06
(JP/US/EU/Asia) HER2+ BC 1L
DESTINY-Breast09
(JP/US/EU/Asia) HER2+ BC
neoadjuvant
DESTINY-Breast11
(US/EU/Asia) HER2 low BC,
HER2 IHC 0 BC, 2/3L
DESTINY-Breast15
(JP/EU/Asia) HER2+ GC 2L
DESTINY-Gastric04
(JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or
exon 20 mutation) 1L
DESTINY-Lung04
(JP/US/EU/Asia) NSCLC 2/3L
TROPION-Lung01
Filed
(JP/EU) HER2 mutant NSCLC 2L+
DESTINY-Lung01/Lung02
DS-6000 (JP/US)
Renal cell carcinoma, ovarian cancer
ENHERTUⓇ
Dato-DXd
HER3-DXd
DS-7300
DS-6000
(JP/US/EU/Asia) non-squamous NSCLC (w/o
AGA, pembrolizumab combo) 1L
TROPION-Lung07
(JP/US/EU/Asia) NSCLC (w/o AGA,
pembrolizumab combo) 1L
TROPION-Lung08
(JP/US/EU/Asia) BC*2 2/3L
TROPION-Breast01
* 1
* 2
Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
Breakthrough Designation (US)
Orphan drug designation (designated in at least one country/region among JP, US and EU)
Adjuvant therapy for HER2 positive breast cancer patients with residual invasive disease following neoadjuvant therapy
HR+, HER2 low or negative BC
*3 Adjuvant therapy for TNBC patients with residual invasive disease following neoadjuvant therapy
AGA: actionable genomic alterations, BC: breast cancer, CRC: colorectal cancer, CRPC: castration-resistant prostate cancer, ESCC: esophageal squamous cell carcinoma,
ES-SCLC: extensive stage-small cell lung cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer
(JP/US/EU/Asia) TNBC 1L
TROPION-Breast02
(JP/US/EU/Asia) TNBC (mono or
durvalumab combo) adjuvant*3
TROPION-Breast03
(JP/US/EU/Asia) EGFR mutated
NSCLC 2L
HERTHENA-Lung02
35View entire presentation